Filing Flows › 8-K events › Abeona Therapeutics
Abeona Therapeutics: results of operations
Form 8-K filed Nov 9, 2026 · items 2.02, 7.01
FDA decisionsAbeona Therapeutics ® Reports Third Quarter 2026 Financial Results and ZEVASKYN ® Commercial Progress
What the filing says
Abeona Therapeutics ® Reports Third Quarter 2026 Financial Results and ZEVASKYN ® Commercial Progress – Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 –
ScaleThe filing names $13.5M: about 30% of Abeona Therapeutics' annual revenue ($45.5M, four times the latest quarter).
Read the filing on SEC EDGAR →
What usually followsAcross 69,249 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →
Abeona Therapeutics at a glance
Abeona Therapeutics, Q2 2026: revenue $11.4M (28× year over year), operating margin -120.0%. The chart follows the revenue to costs, profit and cash.
Abeona Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →
Abeona Therapeutics’s other material 8-Ks
- Nov 9, 2026 — FDA decisions Abeona Therapeutics ® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $3
Other recent fda decisions
- Cabaletta Bio Nov 9, 2026
- Abeona Therapeutics Nov 9, 2026
- ImmunityBio Nov 9, 2026
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Entera Bio Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Microbot Medical Nov 5, 2026
- Bioxytran Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.